Bevatas 100mg Injection (Bevacizumab)

Bevatas 100mg Injection is an anticancer medicine with Bevacizumab as an active ingredient. It prescribes to treat certain types of cancer such as cancer of colon and rectum, non-small cell lung cancer, kidney cancer, brain tumor, ovarian and cervical cancer. It works by preventing the growth of new blood vessels that feed tumors and stops tumors from growing. It is an effective medicine and first-line of treatment when used in combination with other cancer medicines.

colorectal cancer

The human body reacts differently to Bevatas 100mg Injection(Bevacizumab 100mg). Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention.

Some of the common side effects of Bevatas 100mg:
● Nosebleeds
● Headache
● High blood pressure
● Inflammation of the nose
● Protein in urine
● Taste change
● Dry skin
● Hemorrhage
● Increased lacrimation
● Back pain
● Exfoliative dermatitis
However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Bevatas 100mg(Bevacizumab 100mg Injection) is available in injection form and is advised to be taken as per the doctor's prescription. It can only be given intravenously by a doctor or nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects. In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.

● Bahar, I., Kaiserman, I., McAllum, P., Rootman, D., & Slomovic, A. (2008). Subconjunctival bevacizumab injection for corneal neovascularization. Cornea, 27(2), 142-147.
● Davidorf, F. H., Mouser, J. G., & Derick, R. J. (2006). Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina, 26(3), 354-356.
● Bakri, S. J., Snyder, M. R., Reid, J. M., Pulido, J. S., & Singh, R. J. (2007). Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 114(5), 855-859.
● Shima, C., Sakaguchi, H., Gomi, F., Kamei, M., Ikuno, Y., Oshima, Y., ... & Tano, Y. (2008). Complications in patients after intravitreal injection of bevacizumab. Acta ophthalmologica, 86(4), 372-376.
● Mason III, J. O., Nixon, P. A., & White, M. F. (2006). Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. American journal of ophthalmology, 142(4), 685-688.